Telangiectasia Clinical Trial
Official title:
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.
This study is a randomized, interventional case series. A total of 10 patients, seen in the
Retina Division of the Wilmer Eye Institute, will be enrolled. Subjects will be randomized
to either 0.3 mg or 0.5 mg intravitreal injections of ranibizumab. Patients with IPT with
macular edema documented on optical coherence tomography (OCT) but no choroidal
neovascularization will be eligible for this study. Exclusion criteria will include other
forms of retinopathy, active intraocular inflammation, history of poor vision due to
conditions other than IPT in either eye, and known hypersensitivity to humanized monoclonal
antibodies.
After obtaining informed consent, the patient will undergo baseline assessment including
best-corrected Early Treatment for Diabetic Retinopathy Study (ETDRS) visual acuity, ocular
examination, color fundus photography, fluorescein angiography, and OCT. If both eyes are
eligible, the study participant and investigator will choose which eye to be considered the
study eye. The study eye will be assigned at random to receive an intravitreal dose of
ranibizumab (0.3 mg/0.05 ml or 0.5 mg/0.05 ml) at the baseline, 1 month, and 2 month visits.
Further monthly injections are at the discretion of the examiner, and may be withheld if
there is lack of continued improvement (defined as lack of improvement of at least 5 letters
on an eye chart compared with 2 previous consecutive visits or lack of decrease of the
retinal center point thickness of at least 50 microns compared with 2 previous consecutive
visits) or complete success (defined as visual acuity of 20/20 or better or retinal center
point thickness <225 microns).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Terminated |
NCT04336163 -
Skin Imaging to Inform Laser Treatments
|
N/A | |
Completed |
NCT02286804 -
Ultherapy for the Treatment of Spider Veins on the Legs
|
N/A | |
Completed |
NCT03472859 -
Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser
|
N/A | |
Completed |
NCT01491620 -
Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
|
N/A | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Completed |
NCT04148950 -
Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease
|
N/A | |
Completed |
NCT00457067 -
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
|
Phase 1 | |
Completed |
NCT00457145 -
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
|
Phase 1 | |
Completed |
NCT04795310 -
Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia
|
N/A | |
Completed |
NCT04274842 -
D-OCT of Facial Telangiectasia Treated With IPL
|
N/A | |
Recruiting |
NCT05978986 -
Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence
|
N/A | |
Completed |
NCT05036200 -
Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma
|
N/A |